These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 11264455)

  • 1. The basic and clinical pharmacology of nonpeptide vasopressin receptor antagonists.
    Thibonnier M; Coles P; Thibonnier A; Shoham M
    Annu Rev Pharmacol Toxicol; 2001; 41():175-202. PubMed ID: 11264455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular pharmacology of human vasopressin receptors.
    Thibonnier M; Conarty DM; Preston JA; Wilkins PL; Berti-Mattera LN; Mattera R
    Adv Exp Med Biol; 1998; 449():251-76. PubMed ID: 10026814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular pharmacology and modeling of vasopressin receptors.
    Thibonnier M; Coles P; Thibonnier A; Shoham M
    Prog Brain Res; 2002; 139():179-96. PubMed ID: 12436935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and therapeutic indications of orally-active non-peptide vasopressin receptor antagonists.
    Paranjape SB; Thibonnier M
    Expert Opin Investig Drugs; 2001 May; 10(5):825-34. PubMed ID: 11322860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and therapeutic indications of orally-active non-peptide vasopressin receptor antagonists.
    Thibonnier M
    Expert Opin Investig Drugs; 1998 May; 7(5):729-40. PubMed ID: 15991964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vasopressin dysregulation: hyponatremia, fluid retention and congestive heart failure.
    LeJemtel TH; Serrano C
    Int J Cardiol; 2007 Aug; 120(1):1-9. PubMed ID: 17346825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands.
    Serradeil-Le Gal C; Wagnon J; Valette G; Garcia G; Pascal M; Maffrand JP; Le Fur G
    Prog Brain Res; 2002; 139():197-210. PubMed ID: 12436936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The physiological and pathophysiological functions of renal and extrarenal vasopressin V2 receptors.
    Juul KV; Bichet DG; Nielsen S; Nørgaard JP
    Am J Physiol Renal Physiol; 2014 May; 306(9):F931-40. PubMed ID: 24598801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonpeptide vasopressin antagonists: a new group of hormone blockers entering the scene.
    Mayinger B; Hensen J
    Exp Clin Endocrinol Diabetes; 1999; 107(3):157-65. PubMed ID: 10376439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vasopressin-receptor antagonists.
    Hoorn EJ; Zietse R
    Future Cardiol; 2010 Jul; 6(4):523-34. PubMed ID: 20608824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vasopressin release, water channels, and vasopressin antagonism in cardiac failure, cirrhosis, and pregnancy.
    Schrier RW; Fassett RG; Ohara M; Martin PY
    Proc Assoc Am Physicians; 1998; 110(5):407-11. PubMed ID: 9756091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonpeptide antagonists for vasopressin receptors. Pharmacology of SR 121463A, a new potent and highly selective V2 receptor antagonist.
    Serradeil-Le Gal C
    Adv Exp Med Biol; 1998; 449():427-38. PubMed ID: 10026834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic potential of vasopressin-receptor antagonists in heart failure.
    Izumi Y; Miura K; Iwao H
    J Pharmacol Sci; 2014; 124(1):1-6. PubMed ID: 24401675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of interactions responsible for vasopressin binding to human neurohypophyseal hormone receptors-molecular dynamics study of the activated receptor-vasopressin-G(alpha) systems.
    Slusarz MJ; Giełdoń A; Slusarz R; Ciarkowski J
    J Pept Sci; 2006 Mar; 12(3):180-9. PubMed ID: 16114100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conivaptan: a dual vasopressin receptor v1a/v2 antagonist [corrected].
    Ali F; Raufi MA; Washington B; Ghali JK
    Cardiovasc Drug Rev; 2007; 25(3):261-79. PubMed ID: 17919259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyponatremia, arginine vasopressin dysregulation, and vasopressin receptor antagonism.
    Rai A; Whaley-Connell A; McFarlane S; Sowers JR
    Am J Nephrol; 2006; 26(6):579-89. PubMed ID: 17170524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vasopressin antagonists: role in the management of hyponatremia.
    Yeates KE; Morton AR
    Am J Nephrol; 2006; 26(4):348-55. PubMed ID: 16837788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of arginine vasopressin (AVP) on the pituitary-thyroid axis in the rat: Evidence that endogenous AVP, acting via V1 receptors, lowers TSH blood concentration.
    Malendowicz LK; Spinazzi R; Nowak KW; Nussdorfer GG; Majchrzak M
    Int J Mol Med; 2004 Jun; 13(6):869-72. PubMed ID: 15138627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vasopressin receptor antagonists: potential indications and clinical results.
    Arai Y; Fujimori A; Sudoh K; Sasamata M
    Curr Opin Pharmacol; 2007 Apr; 7(2):124-9. PubMed ID: 17292670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats.
    Yamamura Y; Nakamura S; Itoh S; Hirano T; Onogawa T; Yamashita T; Yamada Y; Tsujimae K; Aoyama M; Kotosai K; Ogawa H; Yamashita H; Kondo K; Tominaga M; Tsujimoto G; Mori T
    J Pharmacol Exp Ther; 1998 Dec; 287(3):860-7. PubMed ID: 9864265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.